Mesoblast Targets $100M Revenue Milestone with Ryoncil, Expands Pipeline
Event summary
- Ryoncil® nearing $100M net revenue since 2025 launch, with strategy to double revenues
- Phase 3 trial for chronic low back pain (CLBP) enrollment closing April 2026
- FDA cleared IND for Ryoncil® in Duchenne muscular dystrophy (DMD) registrational trial
- Acquired Mayo Clinic’s patented CAR technology platform to enhance MSC products
The big picture
Mesoblast is positioning itself as a leader in allogeneic cell therapy, leveraging its proprietary platforms to expand into high-value inflammatory disease markets. The acquisition of Mayo Clinic’s CAR technology and strategic label extensions for Ryoncil® underscore its push for blockbuster potential in heart failure and chronic low back pain. The company’s ability to execute on these initiatives will determine its long-term competitive positioning in the rapidly evolving cell therapy space.
What we're watching
- Revenue Growth
- Whether Mesoblast can sustain the pace of Ryoncil® revenue growth and meet its $100M milestone.
- Pipeline Execution
- The pace at which Mesoblast advances its expanded pipeline, particularly in rare diseases like DMD.
- Technology Integration
- How the Mayo Clinic CAR technology platform will enhance Mesoblast’s MSC products and drive differentiation.
Related topics